Scholarlink

Purpose <p>Neuropathological and biomarker evidence implicates tau dysregulation as a downstream component of Huntington’s disease (HD) pathobiology, yet its in vivo distribution has not been characterised using second-generation tau-PET tracers. We aimed to define the regional organisation, stage dependence and clinical relevance of tau-sensitive PET signal across the HD disease spectrum.</p> Methods <p>Fifty-four participants (13 healthy controls, 9 premanifest mutation carriers and 32 manifest carriers) underwent 60-minute dynamic [¹⁸F]PI-2620 PET imaging. Tau-PET signal was quantified using distribution volume ratios (DVR) derived from reference-tissue kinetic modelling. Analyses combined region-of-interest and whole-brain mapping with threshold-based positivity profiling, modelling of cumulative genetic disease burden (CAP), and clinico-anatomical association analyses.</p> Results <p>Tau-PET abnormalities showed a spatially ordered pattern dominated by subcortical involvement. The globus pallidus exhibited the strongest effect, with marked DVR increases and high positivity rates emerging in premanifest carriers and approaching saturation in manifest HD. Additional subcortical changes involved the putamen, whereas caudate DVR decreased in manifest disease. Cortical effects were more modest and selectively involved posterior associative regions. CAP modelling supported predominantly monotonic subcortical stage-related profiles, while limbic and cortical regions showed heterogeneous cross-sectional patterns. Clinico-anatomical analyses linked subcortical tau-PET signal with genetic burden and motor severity and limbic signal with psychiatric symptoms.</p> Conclusion <p>Tau-sensitive PET signal represents a spatially ordered and stage-dependent feature of HD and identifies a reproducible pallidal signature linked to disease burden, supporting its potential as a biomarker for patient stratification and mechanistic monitoring in therapeutic studies targeting downstream pathological processes.</p> Trial registration number <p>NCT07503743.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Stage-dependent tau-PET signatures in Huntington’s disease revealed by [¹⁸F]PI-2620

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月29日

查看全文
  • Saul Martinez-Horta,
  • Jesus Perez-Perez,
  • Arnau Puig-Davi,
  • Valle Camacho,
  • Laura Perez-Carasol,
  • Carla Franch-Marti,
  • Gonzalo Olmedo-Saura,
  • Alex Fernandez-Leon,
  • Albert Flotats,
  • Guilherme D. Kolinger,
  • Santiago Bullich,
  • Esther Perez-Martinez,
  • Javier Pagonabarraga,
  • Jaime Kulisevsky

摘要

Purpose

Neuropathological and biomarker evidence implicates tau dysregulation as a downstream component of Huntington’s disease (HD) pathobiology, yet its in vivo distribution has not been characterised using second-generation tau-PET tracers. We aimed to define the regional organisation, stage dependence and clinical relevance of tau-sensitive PET signal across the HD disease spectrum.

Methods

Fifty-four participants (13 healthy controls, 9 premanifest mutation carriers and 32 manifest carriers) underwent 60-minute dynamic [¹⁸F]PI-2620 PET imaging. Tau-PET signal was quantified using distribution volume ratios (DVR) derived from reference-tissue kinetic modelling. Analyses combined region-of-interest and whole-brain mapping with threshold-based positivity profiling, modelling of cumulative genetic disease burden (CAP), and clinico-anatomical association analyses.

Results

Tau-PET abnormalities showed a spatially ordered pattern dominated by subcortical involvement. The globus pallidus exhibited the strongest effect, with marked DVR increases and high positivity rates emerging in premanifest carriers and approaching saturation in manifest HD. Additional subcortical changes involved the putamen, whereas caudate DVR decreased in manifest disease. Cortical effects were more modest and selectively involved posterior associative regions. CAP modelling supported predominantly monotonic subcortical stage-related profiles, while limbic and cortical regions showed heterogeneous cross-sectional patterns. Clinico-anatomical analyses linked subcortical tau-PET signal with genetic burden and motor severity and limbic signal with psychiatric symptoms.

Conclusion

Tau-sensitive PET signal represents a spatially ordered and stage-dependent feature of HD and identifies a reproducible pallidal signature linked to disease burden, supporting its potential as a biomarker for patient stratification and mechanistic monitoring in therapeutic studies targeting downstream pathological processes.

Trial registration number

NCT07503743.